ES2093812T3 - Un bencenodimetanol adecuado para micronizacion. - Google Patents

Un bencenodimetanol adecuado para micronizacion.

Info

Publication number
ES2093812T3
ES2093812T3 ES92900167T ES92900167T ES2093812T3 ES 2093812 T3 ES2093812 T3 ES 2093812T3 ES 92900167 T ES92900167 T ES 92900167T ES 92900167 T ES92900167 T ES 92900167T ES 2093812 T3 ES2093812 T3 ES 2093812T3
Authority
ES
Spain
Prior art keywords
salt
hydroxy
hydroxynaphthoate
benzenimethanol
micronization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92900167T
Other languages
English (en)
Inventor
Steven Frederick Beach
David William Stuart Latham
Tony Gordon Roberts
Colin Brian Sidgwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2093812T3 publication Critical patent/ES2093812T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTA UNA SAL DE CARBOXILATO DE 1-HIDROXI-2-NAFTALENO (HIDROXINAFTOATO) DE 4-HIDROXI-A1-[[[6-(4FENILBUTOXIDO)HEXIL]AMINO]METIL]-1,3-BENCENODIMETANOL EN FORMA DE ACRECENTAMIENTOS ESFERICOS DE MICROCRISTALES, LOS ACRECENTAMIENTOS ESFERICOS SON DE FLUJO LIBRE, DESMENUZABLES Y MICRONIZABLES Y PREFERIBLEMENTE TIENE UN TAMAÑO MEDIO DE PARTICULA DE ENTRE 70 Y 300 MM Y UN AREA DE SUPERFICIE MEDIA DE ENTRE 4 Y 12 M2G-1. LA SAL DE HIDROXINAFTOATO (EN LA FORMA PRESENTADA) PUEDE PREPARARSE MEDIANTE EL PROCESAMIENTO QUIMICO DE UNA SOLUCION ORGANICA ACUOSA/ORGANICA CALIENTE QUE CONTENGA LA SAL CON UN SOLVENTE ORGANICO ACUOSO/ORGANICO FRIO.
ES92900167T 1990-11-29 1991-11-28 Un bencenodimetanol adecuado para micronizacion. Expired - Lifetime ES2093812T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026005A GB9026005D0 (en) 1990-11-29 1990-11-29 Drug material suitable for micronisation

Publications (1)

Publication Number Publication Date
ES2093812T3 true ES2093812T3 (es) 1997-01-01

Family

ID=10686212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92900167T Expired - Lifetime ES2093812T3 (es) 1990-11-29 1991-11-28 Un bencenodimetanol adecuado para micronizacion.

Country Status (27)

Country Link
US (1) US5380922A (es)
EP (2) EP0639176B1 (es)
JP (1) JP3375626B2 (es)
KR (1) KR100192196B1 (es)
AT (1) ATE144244T1 (es)
AU (1) AU644505B2 (es)
BG (1) BG61340B1 (es)
CA (1) CA2099586C (es)
CY (1) CY2009A (es)
CZ (1) CZ282996B6 (es)
DE (1) DE69122780T2 (es)
DK (1) DK0639176T3 (es)
ES (1) ES2093812T3 (es)
FI (2) FI118155B (es)
GB (1) GB9026005D0 (es)
GR (1) GR3022088T3 (es)
HK (1) HK78997A (es)
HU (1) HU218205B (es)
IE (1) IE914146A1 (es)
OA (2) OA09861A (es)
PL (2) PL167976B1 (es)
RU (2) RU2116293C1 (es)
SG (1) SG49741A1 (es)
SK (1) SK281095B6 (es)
TW (1) TW309425B (es)
WO (1) WO1992009557A1 (es)
ZA (1) ZA919401B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
WO2002026239A1 (en) 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
EP2127641A1 (en) * 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
KR101100614B1 (ko) 2010-09-20 2011-12-29 한국수력원자력 주식회사 농축폐액 건조물의 펠렛화 장치 및 방법과 이를 이용한 유리조성개발 방법
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation

Also Published As

Publication number Publication date
CZ101993A3 (en) 1994-01-19
EP0639176B1 (en) 1996-10-16
HK78997A (en) 1997-06-20
SK281095B6 (sk) 2000-11-07
EP0639176A1 (en) 1995-02-22
FI118155B (fi) 2007-07-31
IE914146A1 (en) 1992-06-03
DE69122780T2 (de) 1997-02-20
FI982081A0 (fi) 1998-09-28
ZA919401B (en) 1992-07-29
HU9301568D0 (en) 1993-09-28
SG49741A1 (en) 1998-06-15
US5380922A (en) 1995-01-10
HUT64219A (en) 1993-12-28
GR3022088T3 (en) 1997-03-31
ATE144244T1 (de) 1996-11-15
BG97767A (bg) 1994-12-02
FI118203B (fi) 2007-08-31
DE69122780D1 (de) 1996-11-21
HU218205B (hu) 2000-06-28
JP3375626B2 (ja) 2003-02-10
OA09861A (en) 1994-08-15
EP0571669B1 (en) 1996-03-06
BG61340B1 (en) 1997-06-30
RU2116293C1 (ru) 1998-07-27
PL169722B1 (pl) 1996-08-30
CA2099586A1 (en) 1992-05-30
CY2009A (en) 1998-02-20
DK0639176T3 (da) 1996-12-23
PL167976B1 (pl) 1995-12-30
AU9040291A (en) 1992-06-25
AU644505B2 (en) 1993-12-09
FI982081A (fi) 1998-09-28
KR100192196B1 (en) 1999-06-15
TW309425B (es) 1997-07-01
CA2099586C (en) 2002-06-25
OA10024A (en) 1996-10-14
JPH06503082A (ja) 1994-04-07
CZ282996B6 (cs) 1997-12-17
EP0571669A1 (en) 1993-12-01
FI932422A (fi) 1993-05-27
FI932422A0 (fi) 1993-05-27
SK54593A3 (en) 1993-10-06
RU2197475C2 (ru) 2003-01-27
WO1992009557A1 (en) 1992-06-11
GB9026005D0 (en) 1991-01-16

Similar Documents

Publication Publication Date Title
ES2077729T3 (es) Procedimiento y dispositivo para la obtencion de particulas esfericas a partir de fase liquida.
ES2093812T3 (es) Un bencenodimetanol adecuado para micronizacion.
MY140392A (en) Powder of amino acids and method for producing the same
RU93040704A (ru) 1-гидрокси-2-нафталинкарбоксилатная соль 4-гидрокси-альфа-[[[6-(4-фенилбутокси)гексил]амино]метил]-1,3-бензолдиметанола в форме сферических сращений микрокристаллов, способ ее измельчения, способ ее получения, применение гидроксинафтоата для получения измельченной гидроксинафтоатной соли
MY108410A (en) Drug material suitable for micronisation.
CA2069256A1 (en) Method of preparing .alpha.-l-aspartyl-l-phenylalanine methyl ester
ES2101177T3 (es) Preparacion de particulas de circonia conformadas.
GR3005944T3 (es)
JPS6467579A (en) Heat accumulator and cooling method thereof
JPS5376463A (en) Crushing method of quickly cooled and solidified powder
Verkhovskii et al. Structure and Properties of Steels After Quenching in Magnetic Liquid
Frommeyer Microstructures of Melt-Atomized and Rapidly Solidified Eutectic Fe--C and Ni--Cr Martensitic White Cast Iron Alloys
Castro et al. Microstructures and solidification kinetics of cast irons: Experimental study and theoretical modelling of equiaxed solidification of sg and grey cast iron
WHITNEY Thomson scattering in a magnetic field(Ph. D. Thesis)
Nakae The Role of Solidification in Developing Materials
NUNNER Directional solidification of aqueous solutions(GERICHTETE ERSTARRUNG VON WAESSRIGEN LOESUNGEN)
JPS5424845A (en) Novel bio-active peptide and its derivative
Jurci et al. Microstructural Development and Phase Transformations in Fe-4 C-12 Cr-13 V RS Powder during Annealing
JPS5360748A (en) Cooling device
Turner On the Anthropic Principle
Kaluzhina Thermogalvanic Corrosion of Iron With Different Temperature Distributions[Previously Titled: Thermogalvanic Corrosion of Iron Under Different Distribution of Surface Temperature.]
Kat Concerning excitonic ferromagnetism.
Brik et al. Effect of Alloying on the Kinetics of gamma-> alpha Transformation in Alloys on the Cerium Base
Golub et al. Temperature Dependence of the Titanium Carbide Young Modulus and Eutectic Chromium--Titanium Carbide Alloys
Burlachuk et al. International congresses on Rorschach test and projective techniques

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 639176

Country of ref document: ES